Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
RA Capital
Biotech
Corxel secures $287M series D to fund oral GLP-1 studies
Shanghai-headquartered Corxel licensed the ex-China rights to the drug, dubbed CX11, from Vincentage in late 2024.
James Waldron
Jan 22, 2026 10:22am
Ramaswamy-backed Ambros launches with $125M to develop pain med
Dec 16, 2025 1:32pm
Freenome to go public in $330M SPAC deal
Dec 5, 2025 10:35am
Triana crafts $120M series B to take glue degrader into clinic
Dec 3, 2025 10:35am
Artios Pharma widens clinical ambitions with $115M series D
Nov 17, 2025 8:00am
Electra shines with $183M fundraise for rare disease trial
Oct 22, 2025 8:26am
